Skip to main content
. 2014 Jan 15;7(2):509–520.

Figure 5.

Figure 5

Tim-1-Fc suppresses Th17 cell differentiation. Bm12-derived cardiac grafts were implanted into T-bet-/- recipients, and Tim-1-Fc or control IgG were administered as described earlier. The recipient mice were sacrificed 14 day after transplantation, and splenic T cells were prepared for flow cytometry analysis of Th17 production. A: Results for IL-17 producing Th17 cells. Splenic T cells were stained for CD4 and then co-stained for IL-17, IL-4 and IFN-γ, respectively. A significant reduction for CD4 Th17 cells was noted in Tim-1-Fc treated recipient mice. B: Results for flow cytometry analysis of IL-17 producing CD8 T cells. The above prepared splenic T cells were first stained for CD8 and then co-stained for IL-17. Staining of CD4 Th17 cells was used as a control. No detectable change was noted for IL-17 producing CD8 T cells. C: Tim-1-Fc dose-dependently suppressed the production of CD4 Th17 cells. CD4 naive T cells were cultured under Th17 condition in the presence of different doses of Tim-1-Fc or control IgG for 3 days, and then subjected to flow cytometry analysis of Th17 production. D: Tim-1-Fc attenuated DC induced Th17 differentiation. CD4 naive T cells were induced for Th17 differentiation with DCs in the presence of Tim-1-Fc or control IgG as described. All data are shown as means ± SD of 3 independent experiments conducted.